In the last trial cohort, two of the six total patients have had a partial response, i.e. tumor reduction of more than 30%, which is considered an important measurement of the effect of cancer treatments. This cohort utilized a four-day dosing schedule.
“It's fantastic that we observed an impressive tumor shrinkage in two of six patients in this cohort. This further strengthens our belief in the program and the potential of SCO-101 as a combination treatment of mCRC, a disease which is today characterized by high mortality rates and massive problems due to drug resistance. Together with the recently announced positive topline, we are convinced that our strategy to further clinical development is crucial for SCO-101 to reach its potential as a key tool to increase the efficacy of chemotherapy,” said
The CORIST Part 3 trial evaluates Scandion’s lead compound SCO-101 as a combination treatment with FOLFIRI chemotherapy in 25 patients with metastatic colorectal cancer (mCRC) and previously demonstrated resistance to FOLFIRI. The trial included 25 patients in 4 cohorts of which 21 patients were evaluable in 2 different schedules. The patients were heavily pretreated and no other active treatment options were available. Part 3 of the trial is designed to provide an optimized dose and schedule for SCO-101 and chemotherapy to ensure maximum effect in patients with mCRC.
In
Based on the positive outcome of part 3 we will design next steps of the study in one or more smaller patient cohorts to further optimize the dose of irinotecan in combination with SCO-101.
For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com
This information is information that
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.
Scandion is based in
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.
© Modular Finance, source